Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RT who wrote (5578)	2/21/1998 12:05:00 PM
From: DR. BOND	Read Replies (2) \| Respond to of 23519

RT....One possible explanation for why refills do not exceed new scripts is that most refills are at the 1,000 mg dosage (which is in great demand and short supply) while most new scripts are at the 250 and 500 mg level, where their is more availability of product. But for an exact answer, please allow me to ask my contacts at VVUS and on the St. and I will report back late monday or tuesday. Thanx, DB

To: RT who wrote (5578)	2/22/1998 6:31:00 AM
From: Robert D	Read Replies (1) \| Respond to of 23519

RT, Anyway you look at it, after 1 year of selling MUSE at any repeat rate over 10%, refills SHOULD be higher than new scripts. I think the McDonald analogy is good. They must be doing way more repeat than new customers... **I will consult a mathematician for some answers. No need for one... Repeat scripts are people that USE the product, Using MUSE is not something you do 2-3 times a year...A kit per month is a minimum I would think. Now with DB numbers (which I assume are correct) that would mean approx. 16K to 20K men who are USING it... Yep, MUCH to low!!! Awaiting last year's numbers to understand this Bob